Blood test may spot cancer return weeks earlier after CAR-T
NCT ID NCT05675982
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tracks 40 patients with aggressive B-cell lymphoma who have received CAR-T cell therapy. Researchers take a blood sample 7 days after treatment to look for leftover tumor DNA. The goal is to see if they can report results within 3 weeks, giving doctors a head start to treat a possible relapse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could enable doctors to detect lymphoma relapse earlier after CAR-T therapy and intervene sooner, potentially improving survival.
- What could go wrong
- This is a small, early-stage observational study focused on feasibility, not treatment. It may not prove that earlier detection actually improves outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Henri Becquerel
Rouen, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a Light-Based device spot dangerous infection risk without a blood draw?